Paclitaxel in combination with carboplatin or gemcitabine for the treatment of advanced head and neck cancer
Loading...
Date
Authors
Fountzilas, G.
Athanassiades, A.
Kalogera-Fountzila, A.
Samantas, E.
Bacoyiannis, C.
Briassoulis, E.
Pavlidis, N.
Kosmidis, P.
Skarlos, D.
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Type
Type of the conference item
Journal type
peer-reviewed
Educational material type
Conference Name
Journal name
Semin Oncol
Book name
Book series
Book edition
Alternative title / Subtitle
Description
We performed a phase II study to evaluate the activity and toxicity of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and carboplatin as first-line treatment in patients with recurrent or metastatic head and neck cancer. From March 1994 until August 1996, 49 patients were treated with paclitaxel 200 mg/m2 by 3-hour infusion followed by carboplatin at an area under the concentration-time curve of 7 mg/mL x min; treatment was requested every 4 weeks. Granulocyte colony-stimulating factor was administered prophylactically on days 2 to 12 of each cycle. The study included 41 men and eight women, with a median age of 57 years (range, 23 to 73 years). Most of the patients were symptomatic and had locoregional disease. Primary sites included nasopharynx (14 patients), oropharynx (six), oral cavity (four), hypopharynx (three), larynx (20), paranasal sinuses (one), and unknown (one). After the completion of treatment, four patients (8%; 95% confidence interval, 0% to 16%) achieved a complete response and 12 (24%; 95% confidence interval, 12% to 37%) achieved a partial response. Grade 3/4 toxicities included anemia (2%) and leukopenia, thrombocytopenia, nausea/vomiting, diarrhea, and stomatitis (4% each). After a median follow-up of 15.3 months, median time to progression was 5.7 months (range, 0.5 to 29.8+ months) and median survival was 13.3 months (range, 0.5 to 30.2+ months). In our ongoing study in a similar patient population, gemcitabine was substituted for carboplatin.
Description
Keywords
Adult, Aged, Alopecia/chemically induced, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use, Carboplatin/administration & dosage/toxicity, Deoxycytidine/administration & dosage/analogs & derivatives, Drug Administration Schedule, Female, Head and Neck Neoplasms/*drug therapy, Humans, Immunosuppression, Male, Middle Aged, Neoplasm Metastasis, Neoplasm Recurrence, Local, Paclitaxel/administration & dosage/toxicity
Subject classification
Citation
Link
http://www.ncbi.nlm.nih.gov/pubmed/9427262
Language
en
Publishing department/division
Advisor name
Examining committee
General Description / Additional Comments
Institution and School/Department of submitter
Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής